ICON Public Limited Company

ICON said Q1 revenue was $2.0 billion, up 0.9% year over year but down 1.9% on a constant-currency basis. Adjusted gross margin was 24.4% versus 28.4% in Q1 2025, adjusted EBITDA was $317.7 million versus $398 million, and adjusted EBITDA margin was 15.6% versus 19.8%. Adjusted net income was $192.9 million and adjusted EPS was $2.50; GAAP net income was $104.8 million, or $1.36 per diluted share. Cash from operations was $167 million, capital expenditures were $30.8 million, and free cash flow was $136.2 million. Full-year 2026 guidance was reiterated at revenue of $7.85 billion to $8.15 billion and adjusted diluted EPS of $10 to $11, with the full-year adjusted tax rate expected to be about 17%.

Barry Balfe emphasized that the quarter was in line with expectations and reflected continued progress in commercial execution. He pointed to stronger diversification in large pharma, more penetration in midsized pharma, and better RFP flow and win rates in biotech, saying the strategy is resonating with customers. He also said the company is seeing encouraging momentum in oncology, cardiometabolic, labs, and digital/AI initiatives, while still navigating near-term headwinds.

Nigel Clerkin focused on the margin bridge and balance sheet. He noted adjusted EBITDA margin of 15.6%, said Q2 margin should progress by about 0.5 points to around 16%, and reiterated that the full-year midpoint implies roughly 16.5% EBITDA margin. He also said pass-through revenue fell by about $100 million from Q4 to Q1, Q1 free cash flow was $136.2 million, cash was $765.2 million, debt was $3.4 billion, and net debt was $2.6 billion, with leverage at 1.8x net debt to trailing EBITDA. Buybacks remain the top capital deployment priority, with repurchases expected to resume in Q3 when the company exits the close period.

Analysts focused on the widening gap between backlog and performance obligations, cancellations, pipeline quality, pricing, margin progression, and cash flow cadence. Management said the backlog/performance obligations gap was driven by strong bookings and seasonality in signings, and that Q2 looked like a strong signing quarter. On cancellations, Barry Balfe said Q1’s $383 million level was unusually low and should not be treated as a new normal, but he did not expect a return to the concerning levels seen previously. They also said pricing remains a continuing 'knife fight,' while the stronger bookings mix, especially in full service and labs, is more relevant to 2027 than 2026.